William E. Rote's most recent trade in Travere Therapeutics Inc was a trade of 4,920 Common Stock done . Disclosure was reported to the exchange on May 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | William E. Rote | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 103,439 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | William E. Rote | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 3,198 | 100,241 (0%) | 0% | 21.1 | 67,318 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 0 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 103,719 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 5,200 | 98,519 (0%) | 0% | 23.5 | 122,356 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 104,670 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 31 Jan 2025 | 8,951 | 95,719 (0%) | 0% | 19.8 | 177,051 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 2,437 | 83,170 (0%) | 0% | 19.5 | 47,424 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 88,842 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 4,387 | 84,455 (0%) | 0% | 11.5 | 50,538 | Common Stock |
| Travere Therapeutics Inc | William Rote E. | SENIOR VICE PRESIDENT, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | William Rote E. | SENIOR VICE PRESIDENT, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 85,484 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | E. Rote William | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 31 Jan 2024 | 2,590 | 80,720 (0%) | 0% | 8.9 | 22,947 | Common Stock |
| Travere Therapeutics Inc | William Rote E. | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 2,174 | 83,310 (0%) | 0% | 8.5 | 18,548 | Common Stock |
| Travere Therapeutics Inc | Rote William E. | SENIOR VICE PRESIDENT, R&D | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 23 Jan 2024 | 2,062 | 60,484 (0%) | 0% | 9.0 | 18,476 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 825 | 59,211 (0%) | 0% | 16.6 | 13,687 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 62,626 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 31 Jan 2023 | 2,590 | 60,036 (0%) | 0% | 22.3 | 57,628 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 24 Jan 2023 | 2,062 | 42,376 (0%) | 0% | 21.5 | 44,333 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 21.52 per share. | 11 May 2022 | 813 | 43,672 (0%) | 0% | 21.5 | 17,493 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 11 May 2022 | 750 | 44,485 (0%) | 0% | 21.9 | 16,448 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 39,360 | 39,360 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 46,360 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,000 | 8,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 31 Jan 2022 | 1,125 | 45,235 (0%) | 0% | 27.4 | 30,825 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 24 Jan 2022 | 1,875 | 36,520 (0%) | 0% | 25.0 | 46,838 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 5,000 | 40,895 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 10 Jan 2022 | 2,500 | 38,395 (0%) | 0% | 27.4 | 68,500 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 4,500 | 37,138 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 1,407 | 35,731 (0%) | 0% | 17.1 | 24,085 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 11 May 2021 | 1,563 | 33,269 (0%) | 0% | 19.1 | 29,916 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 11 May 2021 | 1,562 | 31,707 (0%) | 0% | 19.5 | 30,397 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 27.35 per share. | 17 Feb 2021 | 1,250 | 36,082 (0%) | 0% | 27.4 | 34,188 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 28.67 per share. | 17 Feb 2021 | 1,250 | 34,832 (0%) | 0% | 28.7 | 35,838 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 2,250 | 39,582 (0%) | 0% | 31.4 | 70,673 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 2,250 | 37,332 (0%) | 0% | 31.6 | 71,055 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,500 | 41,832 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 2,500 | 38,457 (0%) | 0% | 28.9 | 72,275 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 1,125 | 37,332 (0%) | 0% | 28.9 | 32,524 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 5,000 | 44,582 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 2,500 | 40,957 (0%) | 0% | 30.8 | 76,875 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 1,125 | 43,457 (0%) | 0% | 30.8 | 34,594 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 57,500 | 57,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 15,000 | 39,582 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 23.96 per share. | 16 Nov 2020 | 2,500 | 24,086 (0%) | 0% | 24.0 | 59,900 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 5,000 | 29,086 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 23.62 per share. | 11 Nov 2020 | 2,500 | 26,586 (0%) | 0% | 23.6 | 59,056 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 23 Sep 2020 | 1,500 | 24,086 (0%) | 0% | 18.5 | 27,720 | Common Stock |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 3,000 | 27,086 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | William E. Rote | Senior Vice President, R&D | Sale of securities on an exchange or to another person at price $ 18.59 per share. | 18 Sep 2020 | 1,500 | 25,586 (0%) | 0% | 18.6 | 27,885 | Common Stock |